Loading...
OTCM
ORINF
Market cap13bUSD
, Last price  
Name

Orion Oyj

Chart & performance

D1W1MN
OTCM:ORINF chart
P/E
—
P/S
—
EPS
3.56
Vol. 1Y
—
Shs. 5Y
0.02%
Rev. 5Y
11.88%
Div Yld LY
—
Div Yld TTM
—
Revenues
1.89b
+22.50%
311,200,000683,600,000710,700,000771,500,000849,900,000917,900,000980,300,0001,006,900,0001,015,300,0001,015,600,0001,073,500,0001,084,700,000977,400,0001,050,900,0001,078,100,0001,041,000,0001,340,700,0001,189,600,0001,542,400,0001,889,500,000
Net income
500m
+51.65%
66,600,000145,400,000136,300,000151,400,000184,700,000209,500,000208,900,000206,200,000211,300,000208,200,000249,000,000226,000,000330,300,000200,400,000219,900,000193,800,000349,500,000216,800,000329,900,000500,300,000
CFO
317m
+7.98%
81,600,000150,900,000144,400,000204,600,000209,100,000198,900,000221,000,000215,200,000296,700,000254,900,000249,100,000228,400,000230,900,000270,800,000299,100,000215,700,000434,400,000119,000,000293,400,000316,800,000
Dividend
Mar 26, 20261.0387 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. It specializes in central nervous system disorders, oncology, and respiratory diseases. The firm's customers are specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. The company was founded by Onni Turpeinen, Eemil Tuurala and Wikki Valkama on September 21, 1917 and is headquartered in Espoo, Finland.

Related entities

Subsidiaries
ORION Pharma GmbH

Key people

Hilpi Rautelin
Independent Vice Chairman of the Board · since 2022
Rene Lindell
Chief Financial Officer, Member of the Executive Management Board · since 2024
Satu Ahomaeki
Senior Vice President, Generics and Consumer Health, Member of the Executive Management Board · since 2023
Juhani Kankaanpaeae
Senior Vice President, Global Operations, Fermion, Member of the Executive Management Board · since 2022
Niclas Lindstedt
Senior Vice President, Animal Health, Member of the Executive Management Board · since 2023
Julia Macharey
Senior Vice President, People and Culture, Member of the Executive Management Board · since 2024
Hao Pan
Senior Vice President, Branded Products, Member of the Executive Management Board · since 2023
Jani Korhonen
Employee Representative on the Executive Management Board · since 2018
Liisa Hurme
President, Chief Executive Officer, Member of the Executive Management Board · since 2022
Mikko Kemppainen
General Counsel, Member of the Executive Management Board, Company Secretary · since 2025
Outi Vaarala
Senior Vice President, Research and Development and Innovative Medicines, Member of the Executive Management Board · since 2023
Kari Aho
Independent Director · since 2020
Ari Lehtoranta
Independent Director · since 2017
Veli - Matti Mattila
Independent Chairman for the Board · since 2024
Karen Sorensen
Independent Director · since 2022
Henrik Stenqvist
Independent Director · since 2024
URL
https://www.orionpharma.com/
IPO date
Jul 03, 2006
Employees
3,657
Domiciled in
FI
Incorporated in
FI
Legal address
PL 65
02101 ESPOO
ESPOO FI-02101
FI
Headquarters
Orionintie 1
02200 ESPOO
ESPOO FI-02200
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT